Introduction and marketing status of zenocutuzumab

Zenocutuzumab (trade name: Bizengri) is a humanized bispecific IgG1 monoclonal antibody designed to target HER2 and HER3 receptor, used to treat patients with non-small cell lung cancer (NSCLC) and pancreatic cancer carrying NRG1 gene fusion.

Zetolizumab inhibits the growth and proliferation of tumor cells by simultaneously targeting the HER2 and HER3 receptors and blocking the signaling pathway mediated by the NRG1 fusion protein.

This bispecific design makes it uniquely effective in treating NRG1 fusion-positive cancers.

In the eNRGy study (NCT02912949), zetolizumab showed efficacy in patients with NRG1 fusion-positive advanced cancers, particularly in patients with non-small cell lung cancer and pancreatic cancer.

The study results showed that zetolizumab had significant anti-tumor activity in these patients, and the adverse reactions were mainly low-grade.

2024 an>) for the treatment of adult patients with advanced, unresectable, or metastatic non-small cell lung cancer and pancreatic cancer who carry the NRG1 gene fusion and have disease progression after prior systemic therapy.

This is the first time that the FDA has approved a systemic therapy targeting NRG1 gene fusion, marking a major advance in the treatment of this specific molecular subtype of cancer.

Common adverse reactions include diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions, dyspnea, rash, constipation, vomiting, abdominal pain, and edema.

In addition, the common 3 level or 4Grade laboratory abnormalities include elevated gamma-glutamyltransferase, reduced hemoglobin, reduced sodium, and thrombocytopenia.

Zetolizumab, as an innovative bispecific antibody, provides a new treatment option for patients with non-small cell lung cancer and pancreatic cancer who carryNRG1 gene fusion. Its demonstrated efficacy and safety in clinical trials make it an important treatment option for this specific patient population.

Reference link: https://www.zailaboratory.com